Search results for: Jorge Mestre-Ferrandiz
Filter search results
Biosimilars and HTA: Results of a Roundtable Discussion
9 April 2014
…information, please contact Jorge Mestre-Ferrandiz. [1] All participants of the roundtable had an opportunity to suggest revisions to the draft summary, but the content of the final version is entirely…
How Will Demands for Effectiveness Evidence Change Drug Development?
23 April 2014
…across disciplines and explicit incentives for considering the perspectives of all stakeholders For additional information, please contact Jorge Mestre-Ferrandiz. Download Mestre-Ferrandiz, J., Deverka, P., Pistollato, M. and Rosenberg, E., 2014….
The Expanding Value Footprint of Oncology Treatments
13 May 2014
…A., 2014. The expanding value footprint of oncology treatments. Consulting report. London: Office of Health Economics. For additional information about this study and OHE Consulting, please contact Jorge Mestre-Ferrandiz. …
Spotlight on OHE: Development and Use of Measures of Health Worldwide
16 July 2012
…Dhabi and Lilly Global, led by Nancy Devlin at OHE in collaboration with HAAD, the EuroQol Group and Paul Dolan from LSE. Jon Sussex and Jorge Mestre-Ferrandiz each presented the…
Patient Preferences for Diagnostic Tests Aimed at Managing Antimicrobial Resistance
7 October 2019
…This work was funded by ‘Tackling AMR – A Cross Council Initiative’ (grant ref: MR/N014316/1). Mott, D.J., Hampson, G., Llewelyn, M.J., Mestre-Ferrandiz, J. and Hopkins, M.M., 2019. A Multinational…
G7 Investments in New Antibiotics Would Pay Off – For Everyone
9 December 2022
…new drugs to tackle AMR. OHE Research Paper, London: Office of Health Economics. Available at: https://www.ohe.org/publications/hta-and-payment-mechanisms-new-drugs-ta… Towse, A., Hoyle, C., Goodall, J., Hirsch, M., Mestre-Ferrandiz, J., Rex J. 2017. Time…
Rare Disease Day 2024: Why Do We Care About Rare?
29 February 2024
…the level and speed of uptake of orphan drugs (e.g. Garau et al., 2009; Mestre-Ferrandiz et al., 2010; Garau et al., 2011; and Zamora et al., 2017). Most recently, Henderson et…
European Medicines Pricing and Reimbursement: Now and the Future
1 January 2007
…scenarios that might emerge in the next decade. – Martina Garau and Jorge Mestre-Ferrandiz in the Introduction Contents – Pricing and reimbursement policies in France: current and future trends; Pricing…
Incorporating Life-cycle Price Modelling into Pharmaceutical Cost-effectiveness Evaluations
25 August 2015
…recommending (or not) drugs that will be no longer (or that will be) cost-effective in the future. Access the full paper here. For more information contact Jorge Mestre-Ferrandiz at OHE….